- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- TNX-103, Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 45
- States / cities
- Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Clinical trials in Cleveland, Ohio
This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Cleveland
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
- Interventions
- Tonlamarsen, Placebo
- Drug
- Lead sponsor
- Kardigan, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 13
- States / cities
- Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 10 more
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 76
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
- Conditions
- Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- questionnaire administration, cognitive assessment, psychosocial assessment and care
- Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 65 Years to 120 Years
- Enrollment
- 1,062 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2027
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Duarte, California • Orange, California + 5 more
- Conditions
- Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
- Interventions
- Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Endoscopic Procedure, Questionnaire Administration, Sigmoidoscopy
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
- Interventions
- Paltusotine, Placebo
- Drug
- Lead sponsor
- Crinetics Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Newport Beach, California • New Haven, Connecticut + 14 more
- Conditions
- Primary Heart Transplant, Heart Transplantation, Heart Transplant
- Interventions
- bortezomib, plasmapheresis
- Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • San Francisco, California • New Haven, Connecticut + 9 more
- Conditions
- Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 50
- States / cities
- Fresno, California • Irvine, California • Los Alamitos, California + 43 more
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Postoperative Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Wyoming, Michigan • Cleveland, Ohio
- Conditions
- Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
- Interventions
- Arcevo™ LSA Hybrid Stent Graft System
- Device
- Lead sponsor
- Artivion Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 16 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Mosunetuzumab, Patient Observation, Polatuzumab Vedotin, Positron Emission Tomography, Tisagenlecleucel
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 95
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- AZD4045, Daratumumab, Aldesleukin
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 10
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 7 more